Cite
HARVARD Citation
Gao, Y. et al. (2023). Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China. Cancer. 129 (4), pp. 551-559. [Online].